Citation: Ting Pan, Dinghu Zhang, Guomei You, Xiaoxia Wu, Chenguang Zhang, Xinyu Miao, Wenzhi Ren, Yiwei He, Lulu He, Yuanchuan Gong, Jie Lin, Aiguo Wu, Guoliang Shao. PD-L1 targeted iron oxide SERS bioprobe for accurately detecting circulating tumor cells and delineating tumor boundary[J]. Chinese Chemical Letters, ;2025, 36(1): 109857. doi: 10.1016/j.cclet.2024.109857 shu

PD-L1 targeted iron oxide SERS bioprobe for accurately detecting circulating tumor cells and delineating tumor boundary

Ting Pan ^{a, 1} ,
Dinghu Zhang ^{a, 1} ,
Guomei You ^a ,
Xiaoxia Wu ^{a, *,} ,
Chenguang Zhang ^b ,
Xinyu Miao ^a ,
Wenzhi Ren ^{b, c} ,
Yiwei He ^a ,
Lulu He ^b ,
Yuanchuan Gong ^a ,
Jie Lin ^{b, c, *,} ,
Aiguo Wu ^{b, c, *,} ,
Guoliang Shao ^{a, *,}

a.
Department of Interventional Radiology, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou 310022, China
b.
Ningbo Key Laboratory of Biomedical Imaging Probe Materials and Technology, Cixi Institute of Biomedical Engineering, International Cooperation Base of Biomedical Materials Technology and Application, Chinese Academy of Science (CAS) Key Laboratory of Magnetic Materials and Devices and Zhejiang Engineering Research Center for Biomedical Materials, Ningbo Institute of Materials Technology and Engineering, CAS, Ningbo 315201, China
c.
Advanced Energy Science and Technology Guangdong Laboratory, Huizhou 516000, China

Received Date: 16 October 2023
Revised Date: 28 March 2024
Accepted Date: 2 April 2024
Available Online: 3 April 2024

Figures(7)

Early diagnosis and accurate boundary delineation are the key steps of tumor precision medicine. Circulating tumor cells (CTCs) detection of liquid biopsy can provide abundant information for early diagnosis of cancer. High detection specificity and good enrichment features are two key factors for CTCs accurate identification in peripheral blood sample. For this purpose, iron oxide (IO)-based surface-enhanced Raman scattering (SERS) bioprobes with good biocompatibility, high detection sensitivity, remarkable detection specificity, and good enrichment efficiency, were developed for detecting different types of CTCs. Magnetic SERS bioprobes combined with programmed death ligand-1 (PD-L1) antibody are regarded as an effective way to boost the targeting ability and detection specificity, benefiting for accurately capturing and identifying rare CTCs. Four types of CTCs with different PD-L1 expression were accurately distinguished among white blood cells via high-resolution SERS mapping images and stable Raman signals. Subsequently, CTCs blood samples obtained from the triple negative breast cancer patients were also successfully recognized compared to that of health people, indicating IO@AR@PDA-aPD-L1 SERS bioprobe possessed great potential for CTCs detection in liquid biopsy. Additionally, IO-based bioprobe exhibited excellent dual-modal imaging abilities of high-resolution SERS imaging mode and microimaging magnetic resonance imaging mode. These two highly complementary imaging modes endowed IO-based bioprobes unrivalled capacity in tumor boundary differentiation, supporting tumor accurate resection and precise surgery. To our best knowledge, this is the first time that biocompatible IO-based SERS bioprobes without noble metal element were reported not only for CTCs accurate detection, but also for precise tumor boundary delineation, showing great advantages in tumor diagnosis and treatment.
- Circulating tumor cells,
- Surface-enhanced Raman scattering,
- PD-L1,
- Iron oxide bioprobe,
- Dual-modal imaging,
- Tumor boundaries delineation
1. [1]
  K. Wang, L. Xiong, Z. Zhang, et al., J. Cent. South Univ. 44 (2019) 1275–1280. doi: 10.1007/s11771-019-4086-7
2. [2]
  A. Llombart-Cussac, Breast Cancer Res. Treat. 112 (2008) 15–24. doi: 10.1007/s10549-008-0234-8
3. [3]
  C.L. Shen, T.C. Jiang, Q. Lou, et al., SmartMat 3 (2022) 269–285. doi: 10.1002/smm2.1099
4. [4]
  H. Jiang, Q. Chen, H. Wang, et al., Chin. Chem. Lett. 35 (2024) 108899. doi: 10.1016/j.cclet.2023.108899
5. [5]
  D.P. Winchester, J.M. Jeske, R.A. Goldschmidt, CA. Cancer J. Clin. 50 (2000) 184–200. doi: 10.3322/canjclin.50.3.184
6. [6]
  R. Alcantara, M. Posso, M. Pitarch, et al., Eur. Radiol. 33 (2023) 417–428. doi: 10.1007/s00330-022-09021-w
7. [7]
  P. Puech, O. Rouvière, R. Renard-Penna, et al., Radiology 268 (2013) 461–469. doi: 10.1148/radiol.13121501
8. [8]
  X. Fave, M. Cook, A. Frederick, et al., Comput. Med. Imaging Graph. 44 (2015) 54–61. doi: 10.1016/j.compmedimag.2015.04.006
9. [9]
  P.A. Carney, J.P. Yi, L.A. Abraham, et al., J. Gen. Intern. Med. 22 (2007) 234–241. doi: 10.1007/s11606-006-0036-9
10. [10]
  D.L. Daniels, S.J. Millen, G.A. Meyer, et al., AJR. Am. J. Roentgenol. 148 (1987) 1219–1222. doi: 10.2214/ajr.148.6.1219
11. [11]
  E.D. Poggio, R.L. McClelland, K.N. Blank, et al., Clin. J. Am. Soc. Nephrol. 15 (2020) 1595–1602. doi: 10.2215/cjn.04710420
12. [12]
  D.B. Asante, L. Calapre, M. Ziman, et al., Cancer Lett. 468 (2020) 59–71. doi: 10.1016/j.canlet.2019.10.014
13. [13]
  B.M. Blokker, I.M. Wagensveld, A.C. Weustink, et al., Eur. Radiol. 26 (2016) 1159–1179. doi: 10.1007/s00330-015-3908-8
14. [14]
  F. MacNeill, A. Karakatsanis, Breast 31 (2017) 284–289. doi: 10.1016/j.breast.2016.10.023
15. [15]
  W. Hartwig, J. Werner, D. Jäger, et al., Lancet Oncol. 14 (2013) e476–e485. doi: 10.1016/S1470-2045(13)70172-4
16. [16]
  N. Harbeck, M. Gnant, Lancet 389 (2017) 1134–1150. doi: 10.1016/S0140-6736(16)31891-8
17. [17]
  P. Janiaud, S. Serghiou, J.P.A. Ioannidis, Cancer Treat. Rev. 73 (2019) 20–30. doi: 10.1016/j.ctrv.2018.12.003
18. [18]
  D. Jin, X.X. Peng, Y. Qin, et al., Anal. Chem. 92 (2020) 9877–9886. doi: 10.1021/acs.analchem.0c01387
19. [19]
  Q. Gou, C. Dong, H. Xu, et al., Cell Death Discov. 11 (2020) 955. doi: 10.1038/s41419-020-03140-2
20. [20]
  T.A. Chan, M. Yarchoan, E. Jaffee, et al., Ann. Oncol. 30 (2019) 44–56. doi: 10.1093/annonc/mdy495
21. [21]
  X. Zhou, T. Ren, H. Zan, et al., Front. Immunol. 13 (2022) 864202. doi: 10.3389/fimmu.2022.864202
22. [22]
  Y. Wang, K.C.C. Johnson, M.E. Gatti-Mays, J. Hematol. Oncol. 15 (2022) 118. doi: 10.1186/s13045-022-01335-y
23. [23]
  J. Huynh, K. Patel, J. Gong, et al., Curr. Treat. Options Oncol. 22 (2021) 100. doi: 10.1007/s11864-021-00893-6
24. [24]
  X. Dai, Y. Gao, W. Wei, Semin. Cancer Biol. 85 (2022) 246–252. doi: 10.1016/j.semcancer.2021.04.002
25. [25]
  D. Atanackovic, T. Luetkens, Semin. Cancer Biol. 52 (2018) 198–206. doi: 10.1016/j.semcancer.2018.05.005
26. [26]
  D. Lin, L. Shen, M. Luo, et al., Signal Transduct. Target. Ther. 6 (2021) 404. doi: 10.1038/s41392-021-00817-8
27. [27]
  Z. Shen, A. Wu, X. Chen, Chem. Soc. Rev. 46 (2017) 2038–2056. doi: 10.1039/C6CS00803H
28. [28]
  H. Ruan, X. Wu, C. Yang, et al., ACS Biomater. Sci. Eng. 4 (2018) 1073–1082. doi: 10.1021/acsbiomaterials.7b00825
29. [29]
  Y. Xu, J. Lin, X. Wu, et al., J. Mater. Chem. B 10 (2022) 3808–3816. doi: 10.1039/d2tb00464j
30. [30]
  X. Wu, Y. Xia, Y. Huang, et al., ACS Appl. Mater. Interfaces 8 (2016) 19928–19938. doi: 10.1021/acsami.6b07205
31. [31]
  Y. Xu, D. Zhang, J. Lin, et al., Biomater. Sci. 10 (2022) 1812–1820. doi: 10.1039/d1bm01821c
32. [32]
  Z.W. Sun, Y.Y. Jiang, M. Stenzel, SmartMat 2 (2021) 127–130. doi: 10.1002/smm2.1043
33. [33]
  H. Hu, W. Zhang, L. Lei, et al., Chin. Chem. Lett. 35 (2024) 108765. doi: 10.1016/j.cclet.2023.108765
34. [34]
  X. Wu, L. Luo, S. Yang, et al., ACS Appl. Mater. Interfaces 7 (2015) 9965–9971. doi: 10.1021/acsami.5b02276
35. [35]
  M. Nora Dickson, P. Tsinberg, Z. Tang, et al., Biomicrofluidics 5 (2011) 034119. doi: 10.1063/1.3623748
36. [36]
  H. Liu, X. Gao, C. Xu, et al., Theranostics 12 (2022) 1870–1903. doi: 10.7150/thno.66859
37. [37]
  X.Y. Meng, L. Qiu, G.C. Xi, et al., SmartMat 2 (2021) 466–487. doi: 10.1002/smm2.1058
38. [38]
  Z.Y. Wang, J. Mei, D.Q. Ni, et al., Rare Met. 42 (2023) 1483–1493. doi: 10.1007/s12598-022-02185-w
39. [39]
  G.C. Zheng, I. Pastoriza-Santos, J. Perez-Juste, et al., SmartMat 2 (2021) 446–465. doi: 10.1002/smm2.1047
40. [40]
  Q. Yang, Y.Y. Mao, Q. Liu, et al., Rare Met. 42 (2023) 2928–2948. doi: 10.1007/s12598-023-02309-w
41. [41]
  L.E. Jamieson, S.M. Asiala, K. Gracie, et al., Annu. Rev. Anal. Chem. 10 (2017) 415–437. doi: 10.1146/annurev-anchem-071015-041557
42. [42]
  S. Zhu, B. Deng, F. Liu, et al., ACS Appl. Mater. Interfaces 14 (2022) 8876–8887. doi: 10.1021/acsami.2c01063
43. [43]
  X. Xu, J. Lin, Y. Guo, et al., Biosens. Bioelectron. 210 (2022) 114305. doi: 10.1016/j.bios.2022.114305
44. [44]
  R.E. Wilson, Jr., R. O'Connor, C.E. Gallops, et al., ACS Appl. Mater. Interfaces 12 (2020) 47220–47232. doi: 10.1021/acsami.0c12395
45. [45]
  M. He, J. Lin, O.U. Akakuru, et al., Sci. China Life Sci. 65 (2022) 561–571. doi: 10.1007/s11427-020-1931-9
46. [46]
  Y. Zhou, Q. Chen, S. Zhong, et al., Biosens. Bioelectron. 237 (2023) 115493. doi: 10.1016/j.bios.2023.115493
47. [47]
  E. Feng, T. Zheng, X. He, et al., Sci. Adv. 4 (2018) eaau3494. doi: 10.1126/sciadv.aau3494
48. [48]
  J. Li, Y. Li, P. Li, et al., Acta Biomater. 144 (2022) 1–14. doi: 10.1016/j.actbio.2022.03.036
49. [49]
  J. Lin, J. Zheng, A. Wu, J. Mater. Chem. B 8 (2020) 3316–3326. doi: 10.1039/c9tb02327e
50. [50]
  E. Lenzi, D. Jimenez de Aberasturi, L.M. Liz-Marzán, ACS Sens. 4 (2019) 1126–1137.
51. [51]
  Y. Li, Z. Wang, X. Mu, et al., Biotechnol. Adv. 35 (2017) 168–177. doi: 10.1007/978-3-319-63315-2_15
52. [52]
  W. Duan, Q. Yue, Y. Liu, et al., Chem. Sci. 11 (2020) 4397–4402. doi: 10.1039/d0sc00844c
53. [53]
  A. Samanta, S. Jana, R.K. Das, et al., Nanomedicine 9 (2014) 523–535. doi: 10.2217/nnm.13.222
54. [54]
  P.J. Mergo, J.D. Engelken, T. Helmberger, et al., Imaging 8 (1998) 1073–1078. doi: 10.1002/jmri.1880080511
55. [55]
  J.W. Bulte, T. Douglas, S. Mann, et al., J. Magn. Reson. Imaging 4 (1994) 497–505. doi: 10.1002/jmri.1880040343
56. [56]
  P. Reimer, B. Tombach, Eur. Radiol. 8 (1998) 1198–1204. doi: 10.1007/s003300050535
57. [57]
  F.E. Azami Hassani, F. Slimani, Ann. Med. Surg. 63 (2021) 102187. doi: 10.1016/j.amsu.2021.102187
58. [58]
  M. Sumi, M. Van Cauteren, T. Nakamura, AJR. Am. J. Roentgenol. 186 (2006) 749–757. doi: 10.2214/AJR.04.1832
59. [59]
  D. Artemov, G. Revelon, E. Atalar, et al., Magn. Reson. Med. 41 (1999) 569–574. doi: 10.1002/(SICI)1522-2594(199903)41:3<569::AID-MRM21>3.0.CO;2-Y
60. [60]
  J. Lin, X. Ma, A. Li, et al., Fund. Res. 4 (2024) 858–867. doi: 10.1016/j.fmre.2022.04.018
61. [61]
  G.C. Wang, P. Huang, L. Wang, et al., SmartMat 3 (2022) 522–531. doi: 10.1002/smm2.1092
62. [62]
  J. An, C.Y. Zhao, Z.J. He, et al., Rare Met. 41(2022) 3351–3359. doi: 10.1007/s12598-022-02046-6
63. [63]
  T.T. Zhu, H. Wang, H.W. Gu, et al., J. Nanobiotechnol. 21 (2023) 52. doi: 10.1186/s12951-023-01807-4
64. [64]
  H.J. Cho, S.K. Perikamana, J.H. Lee, et al., ACS Appl. Mater. Interfaces 6 (2014) 11225–11235. doi: 10.1021/am501391z
65. [65]
  S. Heskamp, W. Hobo, J.D. Molkenboer-Kuenen, et al., Cancer Res. 75 (2015) 2928–2936. doi: 10.1158/0008-5472.can-14-3477
66. [66]
  C. Liu, Z. Yao, J. Wang, et al., Cell Death Differ. 27 (2020) 1765–1781. doi: 10.1038/s41418-019-0460-0
67. [67]
  H. Yu, T.A. Boyle, C. Zhou, et al., J. Thorac. Oncol. 11 (2016) 964–975. doi: 10.1016/j.jtho.2016.04.014
68. [68]
  J. Lin, D. Zhang, J. Yu, et al., Anal. Chem. 95 (2023) 4671–4681. doi: 10.1021/acs.analchem.2c05272
69. [69]
  L.L. Wu, X. Meng, Q. Zhang, et al., Chin. Chem. Lett. 35 (2024) 108663. doi: 10.1016/j.cclet.2023.108663
70. [70]
  Y. Cao, X. Ge, Y. Wei, et al., Chin. Chem. Lett. 35 (2024) 108672. doi: 10.1016/j.cclet.2023.108672
71. [71]
  Y. Chen, J. Zhu, J. Ding, et al., Chin. Chem. Lett. 35 (2024) 108706. doi: 10.1016/j.cclet.2023.108706
1. [1]
  Feng Wu , Xuemin Kong , Yixuan Liu , Shuli Wang , Zhong Chen , Xu Hou . Microfluidic-based isolation of circulating tumor cells with high-efficiency and high-purity. Chinese Chemical Letters, 2024, 35(8): 109754-. doi: 10.1016/j.cclet.2024.109754
2. [2]
  Ce Liang , Qiuhui Sun , Adel Al-Salihy , Mengxin Chen , Ping Xu . Recent advances in crystal phase induced surface-enhanced Raman scattering. Chinese Chemical Letters, 2024, 35(9): 109306-. doi: 10.1016/j.cclet.2023.109306
3. [3]
  Ying Hou , Zhen Liu , Xiaoyan Liu , Zhiwei Sun , Zenan Wang , Hong Liu , Weijia Zhou . Laser constructed vacancy-rich TiO_2-x/Ti microfiber via enhanced interfacial charge transfer for operando extraction-SERS sensing. Chinese Chemical Letters, 2024, 35(9): 109634-. doi: 10.1016/j.cclet.2024.109634
4. [4]
  An Lu , Yuhao Guo , Yi Yan , Lin Zhai , Xiangyu Wang , Weiran Cao , Zijie Li , Zhixia Zhao , Yujie Shi , Yuanjun Zhu , Xiaoyan Liu , Huining He , Zhiyu Wang , Jian-Cheng Wang . Nanomedicine integrating the lipidic derivative of 5-fluorouracil, miriplatin and PD-L1 siRNA for enhancing tumor therapy. Chinese Chemical Letters, 2024, 35(6): 108928-. doi: 10.1016/j.cclet.2023.108928
5. [5]
  Chengde Wang , Liping Huang , Shanshan Wang , Lihao Wu , Yi Wang , Jun Dong . A distinction of gliomas at cellular and tissue level by surface-enhanced Raman scattering spectroscopy. Chinese Chemical Letters, 2024, 35(5): 109383-. doi: 10.1016/j.cclet.2023.109383
6. [6]
  Zhihui Zhang , Ru Sun , Chong Bian , Hongbo Wang , Zhen Zhao , Panpan Lv , Jianzhong Lu , Haixin Zhang , Hulie Zeng , Yuanyuan Chen , Zhijuan Cao . A dual-protease-triggered chemiluminescent probe for precise tumor imaging. Chinese Chemical Letters, 2025, 36(2): 109784-. doi: 10.1016/j.cclet.2024.109784
7. [7]
  Cheng-Zhe Gao , Hao-Ran Jia , Tian-Yu Wang , Xiao-Yu Zhu , Xiaofeng Han , Fu-Gen Wu . A dual drug-loaded tumor vasculature-targeting liposome for tumor vasculature disruption and hypoxia-enhanced chemotherapy. Chinese Chemical Letters, 2025, 36(1): 109840-. doi: 10.1016/j.cclet.2024.109840
8. [8]
  Botao QU , Qian WANG , Xiaogang NING , Yuxin ZHOU , Ruiping ZHANG . Deeply penetrating photoacoustic imaging in tumor tissues based on dual-targeted melanin nanoparticle. Chinese Journal of Inorganic Chemistry, 2024, 40(5): 1025-1032. doi: 10.11862/CJIC.20230416
9. [9]
  Jiangshan Xu , Weifei Zhang , Zhengwen Cai , Yong Li , Long Bai , Shaojingya Gao , Qiang Sun , Yunfeng Lin . Tetrahedron DNA nanostructure/iron-based nanomaterials for combined tumor therapy. Chinese Chemical Letters, 2024, 35(11): 109620-. doi: 10.1016/j.cclet.2024.109620
10. [10]
  Xiaohong Wen , Mei Yang , Lie Li , Mingmin Huang , Wei Cui , Suping Li , Haiyan Chen , Chen Li , Qiuping Guo . Enzymatically controlled DNA tetrahedron nanoprobes for specific imaging of ATP in tumor. Chinese Chemical Letters, 2024, 35(8): 109291-. doi: 10.1016/j.cclet.2023.109291
11. [11]
  Fengyun Li , Zerong Pei , Shuting Chen , Gen li , Mengyang Liu , Liqin Ding , Jingbo Liu , Feng Qiu . Multifunctional nano-herb based on tumor microenvironment for enhanced tumor therapy of gambogic acid. Chinese Chemical Letters, 2024, 35(5): 108752-. doi: 10.1016/j.cclet.2023.108752
12. [12]
  Yi Cao , Xiaojiao Ge , Yuanyuan Wei , Lulu He , Aiguo Wu , Juan Li . Tumor microenvironment-activatable neuropeptide-drug conjugates enhanced tumor penetration and inhibition via multiple delivery pathways and calcium deposition. Chinese Chemical Letters, 2024, 35(4): 108672-. doi: 10.1016/j.cclet.2023.108672
13. [13]
  Jingqi Xin , Shupeng Han , Meichen Zheng , Chenfeng Xu , Zhongxi Huang , Bin Wang , Changmin Yu , Feifei An , Yu Ren . A nitroreductase-responsive nanoprobe with homogeneous composition and high loading for preoperative non-invasive tumor imaging and intraoperative guidance. Chinese Chemical Letters, 2024, 35(7): 109165-. doi: 10.1016/j.cclet.2023.109165
14. [14]
  Peide Zhu , Yangjia Liu , Yaoyao Tang , Siqi Zhu , Xinyang Liu , Lei Yin , Quan Liu , Zhiqiang Yu , Quan Xu , Dixian Luo , Juncheng Wang . Bi-doped carbon quantum dots functionalized liposomes with fluorescence visualization imaging for tumor diagnosis and treatment. Chinese Chemical Letters, 2024, 35(4): 108689-. doi: 10.1016/j.cclet.2023.108689
15. [15]
  Biao Huang , Tao Tang , Fushou Liu , Shi-Hui Chen , Zhi-Ling Zhang , Mingxi Zhang , Ran Cui . Quantum dots boost large-view NIR-Ⅱ imaging with high fidelity for fluorescence-guided tumor surgery. Chinese Chemical Letters, 2024, 35(12): 109694-. doi: 10.1016/j.cclet.2024.109694
16. [16]
  Yanhua Chen , Xian Ding , Jun Zhou , Zhaoying Wang , Yunhai Bo , Ying Hu , Qingce Zang , Jing Xu , Ruiping Zhang , Jiuming He , Fen Yang , Zeper Abliz . Plasma metabolomics combined with mass spectrometry imaging reveals crosstalk between tumor and plasma in gastric cancer genesis and metastasis. Chinese Chemical Letters, 2025, 36(1): 110351-. doi: 10.1016/j.cclet.2024.110351
17. [17]
  Yihao Zhang , Yang Jiao , Xianchao Jia , Qiaojia Guo , Chunying Duan . Highly effective self-assembled porphyrin MOCs nanomaterials for enhanced photodynamic therapy in tumor. Chinese Chemical Letters, 2024, 35(5): 108748-. doi: 10.1016/j.cclet.2023.108748
18. [18]
  Ying Gao , Rong Zhou , Qiwen Wang , Shaolong Qi , Yuanyuan Lv , Shuang Liu , Jie Shen , Guocan Yu . Natural killer cell membrane doped supramolecular nanoplatform with immuno-modulatory functions for immuno-enhanced tumor phototherapy. Chinese Chemical Letters, 2024, 35(10): 109521-. doi: 10.1016/j.cclet.2024.109521
19. [19]
  Jiahao Liu , Peng Liu , Junhong Duan , Qiongxuan Xie , Jie Feng , Hongpei Tan , Ze Mi , Ying Li , Yunjie Liao , Pengfei Rong , Wenhu Zhou , Xiang Gao . Macrophages-mediated tumor accumulation and deep penetration of bismuth/manganese biomineralized nanoparticles for enhanced radiotherapy. Chinese Chemical Letters, 2024, 35(12): 109632-. doi: 10.1016/j.cclet.2024.109632
20. [20]
  Wenbin Zhou , Yafei Gao , Xinyu Feng , Yanqing Zhang , Cong Yang , Lanxi He , Fenghe Zhang , Xiaoguang Li , Qing Li . Biomimetic nanoplatform integrates FRET-enhanced photodynamic therapy and chemotherapy for cascaded revitalization of the tumor immune microenvironment in OSCC. Chinese Chemical Letters, 2025, 36(1): 109763-. doi: 10.1016/j.cclet.2024.109763

Get Citation

PDF

XML

Metrics

PDF Downloads(3)
Abstract views(120)
HTML views(4)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142